Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ) (HNSBF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · HNSBF · as of Jun 9, 2026
Key Statistics
Explore Hansa Biopharma AB (publ) Data
hnsbf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
hnsbf competitorsHNSBF
CMVLF
FGHQF
GNFTF
MAYNF
OPORFStock Performance
Full HistoryAbout Hansa Biopharma AB (publ)
Hansa Biopharma AB (publ) is a biopharmaceutical firm, established in 2007 and headquartered in Lund, Sweden. The company specializes in developing immune-modulating treatments, leveraging its unique …
what is hansa biopharma ab (publ) · hnsbf stock overview · hansa biopharma ab (publ) company profile · who is hansa biopharma ab (publ) ceo · hnsbf OTC · hansa biopharma ab (publ) headquarters · hansa biopharma ab (publ) business segments
About Stock Overview & Key Data
Hansa Biopharma AB (publ) (HNSBF) is a Healthcare company in the Biotechnology industry, listed on OTC since Mar 25, 2015. As of the latest trading session, HNSBF stock price is $2.90, with a market capitalization of $245.8M. The stock has returned -3.33% over the past 12 months and -0.34% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Hansa Biopharma AB (publ) stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Hansa Biopharma AB (publ) reported revenue of $222.3M and net income of -$534.1M. For detailed data — including Hansa Biopharma AB (publ) revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Hansa Biopharma AB (publ) (HNSBF) stock price is $2.90. The stock is traded on OTC under the ticker symbol HNSBF. The 52-week range is $2.73 – $4.58.